Causal cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two Phase 3 trials
Donald E. Stull(IQVIA (United States)), Raj Tummala(Hofstra University), Erik Schwetje(AstraZeneca (United States)), Stephanie Bean(IQVIA (United States)), Betsy Williams(IQVIA (United States)), Gabriel Abreu(AstraZeneca (Finland)), Sean O’Quinn(AstraZeneca (Japan))
Cited by 18
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
|The Lancet Rheumatology|2019|478
Optimal recall periods for patient-reported outcomes: challenges and potential solutions
|Current Medical Research and Opinion|2009|413
Benralizumab for the Prevention of COPD Exacerbations
|New England Journal of Medicine|2019|329